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ABSTRACT
Neogenin-1 (NEO1) is a transmembrane receptor involved in axonal guidance, 
angiogenesis, neuronal cell migration and cell death, during both embryonic 
development and adult homeostasis. It has been described as a dependence receptor, 
because it promotes cell death in the absence of its ligands (Netrin and Repulsive 
Guidance Molecule (RGM) families) and cell survival when they are present. Although 
NEO1 and its ligands are involved in tumor progression, their precise role in tumor cell 
survival and migration remain unclear. Public databases contain extensive information 
regarding the expression of NEO1 and its ligands Netrin-1 (NTN1) and Netrin-4 
(NTN4) in primary neuroblastoma (NB) tumors. Analysis of this data revealed that 
patients with high expression levels of both NEO1 and NTN4 have a poor survival rate. 
Accordingly, our analyses in NB cell lines with different genetic backgrounds revealed 
that knocking-down NEO1 reduces cell migration, whereas silencing of endogenous 
NTN4 induced cell death. Conversely, overexpression of NEO1 resulted in higher cell 
migration in the presence of NTN4, and increased apoptosis in the absence of ligand. 
Increased apoptosis was prevented when utilizing physiological concentrations of 
exogenous Netrin-4. Likewise, cell death induced after NTN4 knock-down was rescued 
when NEO1 was transiently silenced, thus revealing an important role for NEO1 in NB 
cell survival. In vivo analysis, using the chicken embryo chorioallantoic membrane 
(CAM) model, showed that NEO1 and endogenous NTN4 are involved in tumor 
extravasation and metastasis. Our data collectively demonstrate that endogenous 
NTN4/NEO1 maintain NB growth via both pro-survival and pro-migratory molecular 
signaling.
INTRODUCTION
Cancer is a complex chronic disease, characterized 
by the uncontrolled growth and dissemination of tumor 
cells. Within the several varieties of cancer, pediatric 
solid tumors represent about 30% of pediatric cancers, 
including brain tumors, rhabdomyosarcoma, Wilms' 
tumor, osteosarcoma, and neuroblastoma (NB) [1]. In 
general, these tumors arise as a result of the imbalance 
between proliferation/apoptosis and cell differentiation 
during development [2]. Particularly, NB arises from 
neural crest cells in the symphatoadrenal lineage that 
develops from the dorsal root ganglion (DRG) and adrenal 
gland [3]. Little is known about the specific genes and 
signaling pathways that are involved in the development 
and spread of this aggressive and highly metastatic disease 
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[3]. Hence, it is important to understand its etiology and 
the molecular mechanisms involved in tumor onset and 
progression control.
In this context, an important molecule is NEO1, 
which is expressed during the development of the 
DRG [4]. NEO1 is a member of the immunoglobulin 
superfamily of transmembrane protein receptors, 
involved in a variety of features associated with tumor 
progression [5] including proliferation [6], angiogenesis 
[7], apoptosis [8], and migration [9] in several tissues, 
during development and in adult homeostasis [reviewed 
in [10]). Both NEO1 and its homologue, the Deleted in 
Colorectal Cancer receptor (DCC) [10], act as dependence 
receptors that induce apoptosis in the absence of their 
ligands (dependence factors) [11]. DCC primarily signals 
upon binding of the Netrin family ligands [12], whereas 
NEO1 signals through ligands of the Repulsive Guidance 
Molecule (RGM) family [8]. However, recent research 
has proposed that NEO1 may also act via Netrin ligands, 
thus avoiding its pro-apoptotic activity and promoting 
a survival factor function [13] in certain physiological 
contexts as described in β-pancreatic islets [14].
The Netrin ligands belong to the superfamily 
of laminin type proteins, which include five distinct 
members including Netrin-1, -2, -3, -4, -5 and –G, where 
NTN1 and NTN4 are the most characterized ligands [13]. 
Structurally, these molecules consist of an N-terminal 
domain, laminin VI, a central domain, laminin V (EGF 
repeated V1, V2, and V3), and one positively charged 
C-terminal domain. NTN4 is the most distant member 
of this family because its primary sequence and globular 
structural domain are more similar to that of Laminin V 
than to that of other Netrins [15]. Netrins bind to their 
receptors, DCC/NEO1 via the Laminin type VI domain 
[13]. Only the C-terminal domain of the ligand has affinity 
for proteoglycans and thus serves to locate Netrins to the 
cell surface or in the extracellular matrix (ECM) [16].
NTN1 is a critical axonal guidance protein 
during embryonic development, cell migration and 
morphogenesis, and its expression has been reported 
in the DRG [4]. Regarding NTN4 expression, it widely 
encompasses the nervous system during embryonic 
development and it is maintained in adult individuals. 
Its expression is centered in the olfactory bulb, retina, 
cerebellar granule cells, hippocampal and cortical neurons, 
and in DRG neurons [15]. The former is of interest, 
considering the fact that NEO1 is expressed in the DRG, 
suggesting a possible interaction between Netrins/NEO1 
in cells that give rise to NB.
The Netrin family of ligands is highly involved 
in a variety of processes associated with tumor 
progression, however their specific contribution remains 
controversial. Although NTN1 was initially reported to be 
downregulated in NB [17], a more recent clinical study 
revealed that NB tissues from stage-4 patients exhibited an 
overexpression of NTN1, conferring a selective advantage 
for survival of NB cells. Disrupting the expression of 
NTN1 further inhibited metastasis in mouse and chicken 
models of NB tumorigenesis [18]. Furthermore, studies 
in vitro and patient samples have demonstrated that the 
interaction between NEO1 and NTN1 is associated with 
cell migration and invasiveness in medulloblastoma, 
another pediatric malignancy [19].
Contrary to the description and analyses of NTN1 
contribution in pediatric cancer, the expression of NTN4 
has not yet been characterized. In glioblastoma, NTN4 
has been proposed to depict a biphasic function: at low 
physiological ligand concentrations, both proliferation and 
cell migration increase, whereas at high concentrations, 
tumor cell growth is inhibited. Reduced NTN4 expression 
in glioblastoma cell lines induced by serum starvation 
significantly decreases proliferation and motility, 
increasing apoptosis. This is consistent with the low 
expression of NTN4 in glioblastoma cells compared to 
its expression in healthy tissue [20]. Endogenous NTN4 
also induces migration and proliferation in gastric cancer 
cells [21]. In breast carcinoma, NTN4 expression is most 
commonly detected in solid tumors than in malignant 
pleural effusions [22]. Combined, these findings suggest 
a possible biological role for NTN4 in tumor metastasis.
Since both NEO1 and Netrins are expressed in the 
DRG neuronal progenitors, which give rise to NB, their 
relationship and interaction might be relevant in the 
oncogenic context. However, little is known about the 
function that NEO1 plays in NB progression, or about the 
autocrine expression of Netrin ligands. Here, we provide 
evidence about novel roles of the NTN4/NEO1 complex 
in NB cell migration, survival, and in vivo metastasis. 
Furthermore, our data contribute to the identification and 
characterization of new therapeutic targets to inhibit NB 
tumor growth.
RESULTS
Expression of NEO1 and Netrins in NB samples 
and cell lines
In order to determine the expression of NEO1 and 
its ligands, NTN1 and NTN4, in primary NB tumors, 
and to further correlate the patient prognosis with patient 
survival, we reviewed public available data from R2: 
Genomics Analysis and Visualization Platform (http://
r2.amc.nl). Specifically, we analyzed the Versteeg data 
set [23] that includes information from 88 patients. Our 
analysis depicts that high levels of NEO1 mRNA (n=58) 
and NTN4 mRNA (n=32) are associated with overall lower 
patient survival rates (raw p value: 0,056 and 0,0014 
respectively), as seen in Figure 1A and 1B, respectively. 
This suggests that NEO1 and its ligand NTN4 have 
potential roles in NB progression. Conversely, higher 
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NTN1 mRNA expression (n=8) was found to be associated 
with lower patient survival rate (Supplementary Figure 
1A).
Considering this evidence, we first sought to 
determine the expression of NEO1 and its ligands in two 
subsets of NB cell lines: SK-N-SH (MYCN WT), LAN-
1 and NB1691 (MYCN amplified). As seen in Figure 1C, 
NEO1 is expressed in all NB cell lines studied, especially 
in SK-N-SH. In addition, NEO1 expression was higher 
in SK-N-SH, when compared to other cancer cell lines 
such as DAOY (medulloblastoma), U87 (glioblastoma), 
and HEK293 cells (Supplementary Figure 1B). Whereas 
NTN1 protein was barely expressed in the SK-N-SH 
cell line, it was detected in the two MYCN amplified 
NB (Supplementary Figure 1C). In addition, the SK-N-
SH cell line did not exhibit RGMa protein expression 
(Supplementary Figure 1D), whereas LAN-1 did. Western 
Blot analysis confirmed the expression of NTN4 by the 
MYCN WT SH-SY5Y and SK-N-SH cell lines (Figure 1D). 
Of note, NTN4 band is predicted at 69 kDa, but we detected 
a single band at 90 kDa, possibly due to post-translational 
modifications of the protein [24]. qPCR analysis revealed 
that SK-N-SH and LAN-1 express NEO1 (data not shown) 
and NTN4 mRNA (Figure 1E). Next, we evaluated the 
Figure 1: Clinical significance of NEO1 and NTN4 expression and characterization of NB cell lines. A, B. Analysis was 
performed using R2 (http://r2.amc.nl) and public primary tumor NB database from 88 patients (Versteeg). The data set is separated into 
two categories, high and low mRNA, depending on where the values lie in relation to the median value: values above the median are high 
mRNA levels and those below the median, are low mRNA levels. These values are then plotted against patient survival rate in a Kaplan-
Meier estimate plot. Observed is the overall survival rate according to mRNA expression of NEO1 (A) and NTN4 (B). C. Western blot 
against NEO1 in NB cell lines SK-N-SH, LAN-1 and NB1891. D. NTN4 expression in NB SH-SY5Y and SK-N-SH cell lines. Of note, 
NTN4 band is predicted at 69 kDa, but we detected a single band at 90 kDa, possibly due to post-translational modifications of the protein, 
as reported in the human Netrin-4 datasheet (R&D systems). E. Q-PCR analysis showing NTN4 expression in SK-N-SH and LAN-1 cells. 
F, G. Representative Western blots of protein co-immunoprecipitation assays used to evaluate interaction between NEO1 and NTN4 in 
SK-N-SH cells. Cells were treated for 1h with exogenous Netrin-4 (200 ng/ml) and then incubated using specific antibodies against either 
NEO1 (F) or NTN4 (G) followed by Western blot against NEO1 and NTN4.
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putative association in a complex between NEO1 and 
NTN4 in SK-N-SH cells, by co-immunoprecipitation. SK-
N-SH cells were incubated for 1h with exogenous Netrin-4 
(200 ng/ml) and immunoprecipitation was performed with 
specific antibodies against NEO1 (Figure 1F) or NTN4 
(Figure 1G). Our Western blot analysis shows clearly 
that NTN4 and NEO1 interact in SK-N-SH, favoring the 
hypothesis that there could be a functional relationship 
between these proteins in NB.
Silencing NTN4 increases apoptosis in NB cells
Having assessed the expression and the interaction 
of NEO1 and NTN4 in both NB tumors and cell lines, 
we next decided to evaluate the potential contribution 
of the NEO1/NTN4 complex signaling in a variety of 
processes associated with tumor progression. It has been 
demonstrated that NTN4 is a survival factor in other 
cellular contexts [14] and NEO1 has been shown to behave 
as a death dependence factor [8]. Therefore, we sought to 
characterize the role of both proteins in our panel of tumor 
cell lines by interfering their expression. Knock-down cells 
for NEO1 (shNEO1) and NTN4 (shNTN4) were generated 
in SK-N-SH cells and in a MYCN amplified LAN-1 cells, 
using a scrambled sequence as negative control (shSCR). 
NTN4 expression was reduced by 70% (Supplementary 
Figure 2A) in SK-N-SH cells and 60% in LAN-1 cells 
(Supplementary Figure 2B). The expression of NEO1 was 
reduced by 60% in SK-N-SH (Supplementary Figure 2C) 
and LAN-1 cells (Supplementary Figure 2D).
In order to evaluate the potential role of NTN4 in cell 
survival, we first analyzed whether silencing endogenous 
NTN4 increases apoptosis in LAN-1 cells grown under 
serum starvation. shNTN4 LAN-1 cells were cultured 
without serum for 24 h and dead cells were analyzed using 
propidium iodide staining, while Hoechst was used to 
stain total nuclei (Figure 2A). We observed an increment 
of cell death in shNTN4 LAN-1 cells, when compared to 
shSCR control (Figure 2B). Next, we analyzed whether 
silencing endogenous NTN4 also increases apoptosis in 
SK-N-SH cells grown under serum starvation, and if so, 
whether this could be reverted with exogenous Netrin-4. 
As NEO1 mediates apoptosis signals through caspase-3 
[25], we conducted immunofluorescence on shSCR and 
shNTN4 SK-N-SH cells labeled with an antibody against 
the cleaved caspase-3 epitope (Figure 2C). Quantification 
of the fluorescence demonstrates that shNTN4 cells 
have a greater cleaved-caspase-3 signal compared to 
that of the shSCR cells under serum-starvation. This 
signal was already reduced in the presence of minimal 
exogenous concentration of Netrin-4 (50ng/mL), and was 
further diminished with higher Netrin-4 concentrations 
(Figure 2D). Recombinant RGMa (100ng/ml) was 
used as a positive control of NEO1-mediated apoptosis 
avoidance [7, 8]. A TUNEL assay, conducted under serum 
deprivation, corroborated that shNTN4 SK-N-SH cells 
showed an increase of TUNEL positive cells compared 
with the control shSCR cells, depicting higher apoptosis 
in shNTN4 cells (Figure 2E). shNTN4 cells treated with 
exogenous Netrin-4 exhibited reduced apoptosis (Figure 
2F). Since knocking down the ligand resulted in increased 
apoptosis, we conclude that endogenous NTN4 behaves as 
a survival factor in NEO1-expressing NB cells.
Interestingly, we also noticed a diminished 
proliferation after silencing NTN4 in SK-N-SH cells 
(Supplementary Figure 3A-3C), although this could be the 
result of increased cell death in shNTN4 cells.
Apoptosis induced by NTN4 silencing is reversed 
upon NEO1 knock-down
NEO1 has been suggested to be a dependence 
receptor in specific cellular contexts driving positive 
cell signaling (proliferation, migration, survival), but 
whether or not NTN4 controls its pro-apoptotic role 
remains unknown. Having demonstrated that NTN4 is 
a survival factor in NB cells, we next analyzed whether 
NEO1 acts as its death dependence factor and as such, if 
its knock-down can revert the apoptosis induced by NTN4 
silencing. For this purpose, we transfected siRNAs against 
NEO1 in shNTN4 SK-N-SH cells. siRNA efficiency 
was analyzed via Western blot and since siNEO1(1) 
reduced NEO1 protein levels significantly (Figure 3A), 
this siRNA sequence was chosen for further analysis. 
shNTN4 cells were transfected with siNEO1(1) and 
siControl and 48 h later, cells were serum starved for 48 
h and fixed. Apoptosis was evaluated via TUNEL (Figure 
3B) and immunofluorescence against Cleaved-Caspase-3 
(Figure 3C). Both assays showed a significant decrease 
in apoptosis in the shNTN4 background when silencing 
NEO1, indicating that NTN4 is a survival factor that 
controls NEO1 pro-apoptotic activity.
NEO1 and NTN4 promote in vitro chemotactic 
cell migration
Considering that NEO1 is involved in neuronal cell 
migration [9], we aimed to address whether this function 
was relevant in the tumor context and if it was dependent 
of its ligand NTN4. Using transwell chemotaxis assays, 
we examined the function of NEO1 in sensing and 
guiding tumor NB cells, and analyzed whether NTN4, 
a known chemotactic molecule, influenced this process. 
Previous studies have revealed a dose-dependent effect 
of NTN4 in glioblastoma cell proliferation and motility 
[20]. Therefore, we compared the migratory behavior of 
shNEO1, shNTN4, and shSCR LAN-1 in the presence of 
100ng/ml of Netrin-4 as a chemoattractant in the bottom 
chamber (representative images shown in Figure 4A). We 
observed that shSCR and shNTN4 LAN-1 cells migrate 
positively towards the chamber containing Netrin-4 
(Figure 4B). Conversely, shNEO1 cells cannot migrate 
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Figure 2: Silencing of NTN4 increases apoptosis in NB cells; exogenous Netrin-4 decreases this effect. A, B. Representative 
images of propidium iodide (PI) staining in shSCR and shNTN4 LAN-1 cell cultures. Cells were serum deprived for 24 h and stained 
with PI and Hoechst; cell death quantification is shown in (B) *p<0,05 shSCR v/s shNTN4. Bar: 200μm. C. Representative images of 
immunofluorescence against cleaved caspase-3 in shSCR and shNTN4 SK-N-SH cells. D. Quantification of cell death rescue experiments 
in SK-N-SH cells. Cells were treated for 24 h in serum free media adding human recombinant Netrin-4 at concentrations as described. 
Human recombinant RGMa (100ng/ml) was used as a control. Bar:100μm E. Representative images of TUNEL assays made in shSCR 
and shNTN4 SK-N-SH cells. Cells were incubated with serum free media with or without NTN4 (200 ng/ml); quantification is shown in F. 
*p<0,05 shSCR v/s shNTN4 (0 and 200 ng/ml). Bar:100 μm.
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positively in presence of Netrin-4 (Figure 4B), therefore, 
these cells cannot sense Netrin-4 as a chemotactic 
molecule, ergo disabling the cell migration execution. 
Next, we wondered if this mechanism was conserved 
in MYCN WT cells, such as SK-N-SH cells, by using 
shSCR, shNEO1 and shNTN4 cells, and by increasing 
concentrations of exogenous Netrin-4 (25, 50, 100 ng/
ml) in the bottom chamber (Figure 4C). The migration of 
shSCR cells augmented with increasing concentrations 
of NTN4 (Figure 4D). Our results depict a negative 
chemotaxis response due to the fact that shNEO1 cells did 
not sense NTN4, which is in line with the results observed 
for the LAN-1 NB cell line. Strikingly, both shNEO1 and 
shNTN4 cells migrated less than shSCR cells and their 
migration did not improve with increasing concentrations 
of Netrin-4 (Figure 4D). Even when we tested higher 
concentrations of Netrin-4 (200 and 500 ng/ml) as a 
chemoattractant stimulus for shNTN4 SK-N-SH cells, 
we did not observe any increases in cell migration (data 
not shown). Previous reports have shown that endogenous 
NTN4 promotes cell migration in gastric cancer cells 
[21]. Indeed, NTN4 is required for proper endothelial cell 
migration, adhesion, and focal adhesion contacts, through 
the binding with a6β1 integrin [26]. This suggests that 
NTN4 might be necessary to initiate NB cell migration, 
possibly acting through non-canonical receptors. The 
difference in shNTN4 cell migration between the two 
NB cell lines is probably due to the differential NTN1 
expression, which is not present in the SK-N-SH cells, 
but is expressed in LAN-1 cells. This protein partially 
rescued the shNTN4 phenotype in the second cell line 
(Supplementary Figure 1C). Together, these results suggest 
that NEO1 promotes cell migration through NTN4 in NB.
We decided to complement our SK-N-SH 
cell migration analysis by performing a functional 
complementary approach, such as the wound healing 
assay, in presence of low serum (2,5%). shNEO1 cells 
migrated significantly less, when compared to shSCR and 
shNTN4 (Figure 4E). Quantification of the wounded area 
is shown in Figure 4F. The impaired wound closure in 
shNEO1 cells confirmed the importance of NEO1 in NB 
cell migration, and thus in tumor migration.
NEO1 regulates apoptosis and cell migration 
through NTN4
Our previous results demonstrate that silencing 
NTN4 increases apoptosis, an effect that is reverted 
after transient NEO1 knock-down (Figure 3). In order to 
validate whether NTN4/NEO1 acts as a signaling complex 
in NB we analyzed the effect of NEO1 overexpression 
in SK-N-SH cells. Relative protein expression analysis 
revealed a two-fold increase in the levels of NEO1 in 
NEO1GFP compared to cells that were transfected with 
an empty vector (EV) (Supplementary Figure 2E, 2F). 
In agreement with our hypothesis, results indicate that 
overexpressing NEO1 (NEO1GFP) increased TUNEL 
positive cells compared to control EV cells, suggesting an 
increase in cell apoptosis (representative images shown in 
Figure 5A). Introducing exogenous Netrin-4 reduced the 
number of TUNEL positive cells, suggesting a reduction 
of apoptosis (Figure 5B). To determine whether NTN4 
acts as a survival factor specifically through NEO1 or 
as a general survival factor, we overexpressed TrkC, a 
dependence receptor that acts as a tumor suppressor in 
NB [27] and repeated TUNEL assays. As expected, TrkC 
induced apoptosis in SK-N-SH cells (Supplementary 
Figure 3D). However, exogenous Netrin-4 did not reduce 
TUNEL positive cells overexpressing TrkC, suggesting 
that NTN4 acts as a survival factor specifically via NEO1. 
Taken together, these results indicate that NEO1 triggers 
apoptosis in the absence of NTN4, whereas the induction 
of cell death is inhibited if NEO1 binds to its ligand.
Figure 3: NEO1 knock-down reverses apoptosis induced by NTN4 silencing in SK-N-SH cells. A. Two siRNA sequences 
were tested to silence NEO1 in NTN4 knock-down cells. Western blot revealed efficient silencing of NEO1 with the siNEO1(1) sequence. 
B. Quantification of TUNEL assay in 48 h serum deprived shNTN4 cells transfected with siRNAs as indicated. *p<0,05 siControl v/s 
siNEO1(1). C. Quantification of immunofluorescence against cleaved Caspase-3 made in 48 h serum deprived shNTN4 cells transfected 
with either siControl or siNEO1(1) *p<0,05 siControl v/s siNEO1(1).
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Figure 4: NEO1, acting through NTN4, promotes in vitro chemotactic cell migration in NB cells. A. Representative images 
of transwell assay with LAN-1 knock-down cells. shSCR, shNEO1, and shNTN4 LAN-1 cells migrated for 6 hours under exogenous 
Netrin-4 (100 ng/ml), added to the serum free media in the botton chamber. Bar:100μm. B. Quantification of LAN-1 transwell assay * 
p<0,05 shSCR or shNTN4 0 v/s 100ng/ml NTN4, α p<0,05 shSCR or shNTN4 v/s shNEO1. C. Representative images of transwell assay 
made with SK-N-SH knock-down cells. shSCR, shNEO1, and shNTN4 SK-N-SH cells migrated for 4 hours under different concentrations 
of exogenous Netrin-4 present in the serum free media placed in the botton chamber. Bar:100μm. D. Quantification of transwell assay * 
p<0,05 shSCR 0 v/s 100ng/ml NTN4, α p<0,05 shSCR v/s shNEO1 or shNTN4. E, F. Wound healing assays of stable knocked-down SK-N-
SH cells using shRNAs as indicated. Representative images (E) were quantified after 9 hours (F). Bar:100μm; *p<0,05 shSCR v/s shNEO1.
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Finally, we decided to analyze the effect of NEO1 
overexpression in the migratory assay. For that, we 
transfected SK-N-SH cells with either a GFP-tagged 
NEO1 (NEO1GFP) or the intracellular fragment of NEO1 
(NEO1ICDGFP), which lacks the extracellular domain 
that binds to the ligands. Supplementary Figure 2E shows 
a scheme of the full-length NEO1 protein indicating the 
NEO1ICD domain localization. Transfection efficiency 
obtained was around 50%. We performed a transwell 
assay with NEO1GFP, NEO1ICDGFP, and EV cells 
using 100ng/mL of Netrin-4 as a chemotactic stimulus 
(representative images shown in Figure 5C). As shown in 
Figure 5D, NEO1GFP overexpressing cells migrated more 
than the control EV cells (α p<0,05) when the chemotactic 
stimulus was introduced, while NEO1ICDGFP cells did 
not exhibit significant migration. The lack of significant 
migration indicates that NEO1ICDGFP transfected cells 
cannot sense the NTN4 stimulus efficiently, probably due 
an interference of NEO1ICDGFP with the downstream 
signaling activities of the endogenous full length NEO1. 
Therefore, in NB cells, endogenous NTN4 acts as a 
survival factor and induces cell migration, both through 
NEO1 binding. Summarizing these results, we can 
conclude that, in NB cells, there is a delicate balance 
between apoptosis and cell migration controlled by the 
NEO1/NTN4 signaling axis.
Figure 5: Overexpression of NEO1 induces apoptosis that can be rescued by exogenous Netrin-4 and promotes cell 
migration through NTN4 chemotaxis. A. Representative images of TUNEL assay made with SK-N-SH cells transfected with NEO1 
(NEO1GFP) or empty vector (EV) and treated for 24 h with serum free media with or without Netrin-4 (200 ng/ml). Bar:100 mm. TUNEL 
positive cells are shown in red and were quantified in B. *p<0,05 EV versus NEO1GFP (0 ng/ml), α *p<0,05 NEO1GFP (0n/ml) vs 
NEO1GFP (200ng/ml Netrin-4). C. Representative images of transwell assays using SK-N-SH cells that overexpress NEO1 (NEO1GFP), 
or its intracellular domain (NEOICDGFP). An empty vector (EV) was utilized as a control. Cells migrated for 4 hours using 100 ng/mL 
Netrin-4 as a chemotactic stimulus Bar: 100μm. D. Quantification of transwell assay shown in (C) * p<0,05, **p<0,001, α p<0,05.
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NEO1 and endogenous NTN4 participate in 
metastasis in vivo
After examining the potential role of endogenous 
NEO1 and NTN4 participating in apoptosis and cell 
migration, we wanted to ascertain whether they also 
participate in primary tumor formation and metastasis in 
vivo. We conducted a chick CAM assay and transplanted 
shNEO1, shSCR, or shNTN4 SK-N-SH cells, to generate 
primary tumors in chicken embryos (representative images 
are shown in Figure 6A). The resulting primary tumors 
were all similar, with no significant differences in tumor 
size and weights among the different transfected cell 
batches (Figure 6B). Importantly, we observed that shSCR 
cells formed secondary tumors in 57,2% of the embryos, 
characterized as GFP+ small nodules on the CAM, near 
the primary tumor (Figure 6C), while shNEO1 and 
shNTN4 transfected cells grew mostly as primary tumors 
(16,6 % shNEO1 and 22,2 % shNTN4; secondary tumor 
formation). The latter result suggests that shNEO1 and 
shNTN4 cells have a reduced capacity to migrate across 
the CAM.
Tumor metastasis involves the migration, invasion, 
and proliferation of tumor cells into other tissues and 
niches. We evaluated metastasis rate in the embryonic 
chicken lungs by amplifying human Alu sequences. The 
Figure 6: NEO1 and endogenous NTN4 participate in spontaneous metastasis in vivo. CAM assays were used to evaluate 
spontaneous metastasis of SK-N-SH cells dropped onto CAMs of chicken embryos on day 10 of incubation (E10). Stable knock-down cells 
shSCR, shNEO1, and shNTN4 were used in this assay. After 7 days (E17) embryos were dissected and lung metastasis was analyzed for 
each cell type. A. Representative images of primary tumor in CAM 5 days post-dropping. Bar: 5 mm. B. Tumor weight from primary tumor 
formed by the different cell lines in CAM. C. On day 5 post-dropping, secondary tumors in CAM were clearly visible and were formed 
by shSCR cells that migrated from primary tumors. This process did not occur in the case of shNEO1 and shNTN4 cells. Bar: 5 mm D. 
Quantification of Q-PCR analysis using genomic DNA of human Alu sequences in lungs to evaluate metastasis for shRNA cells, compared 
with chicken GAPDH gene. *p<0,05.
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PCR results indicate that neither shNEO1 nor shNTN4 
cells metastasized into the lungs (Figure 6D). Overall, 
these results suggest that both NEO1 and NTN4 may 
potentially participate in metastasis in vivo.
DISCUSSION
Tumor metastasis is orchestrated by several cellular 
processes, such as proliferation, cell survival, apoptosis, 
and cell migration [28]. In this work, we show that NEO1 
is involved in all of these processes, recapitulating its 
known role in embryonic development [10]. NEO1 [4, 29] 
and NTN4 [15] are expressed in sites where NB originates, 
such as in the DRG of the embryonic neural crest, and 
we hypothesize that their functions persist throughout 
cancer progression, as a result of an impairment in the 
normal developmental signaling. Clinically, NEO1 
expression endures throughout NB progression [30], 
and often results in poor patient prognosis. Conversely, 
loss of DCC expression, a homolog of NEO1, correlates 
inversely with the degree of NB dissemination [31], acting 
in this context as a tumor suppressor. In line with this 
data, DCC is not expressed in SK-N-SH cells [31] or in 
other NB cell lines [30, 31]. This phenomenon is due to 
the fact that the DCC gene undergoes an allelic loss. In 
fact, reduced expression of DCC [31] has been reported 
in several types of cancer (prostatic, colorectal and NB), 
unlike NEO1, which expression is not altered [30]. The 
expression of NTN4, one of the described ligands of the 
NEO1/DCC receptor family [32, 33], is also associated 
with an overall poor survival rate of NB patients. Overall, 
these results are in agreement with our meta-analysis of 
repository data, confirming that both NTN4 and NEO1 
expression correlates with a worse prognosis, whereas 
NTN1 expression behaves the opposite. In fact, previous 
data from other groups have shown that NTN1 loss of 
expression in both, patient samples and NB cell lines, 
might contribute to progression of NB [17].
Here, we establish that both, WT and high MYCN 
NB cell lines (represented by SK-N-SH and LAN-1), 
express NEO1 and NTN4. In particular, we demonstrate 
that both proteins interact directly in NB cell lines, 
conforming a signaling complex that contributes 
differentially in several tumoral progression processes.
Role of NTN4 in apoptosis
Physiologically, NTN4 promotes angiogenesis 
[34, 24] in endothelial cells [7], driving proliferation, 
migration, and adhesion. Within the cancer context, 
NTN4 could have biphasic roles. At low physiological 
concentrations [24], cells exhibit high proliferation rates 
in glioblastoma [20] and gastric cancer [21]. At high 
concentrations, however, proliferation and angiogenesis 
are inhibited in glioblastoma [20] and colorectal cancer 
[35]. NTN4 could also act as a survival factor, especially 
because it blocks the pro-apoptotic activity of its receptors 
[14]. In fact, NTN4 has been shown to promote survival 
maintenance in beta pancreatic islets [14]. Here, by using 
apoptotic markers, we have confirmed that endogenous 
and exogenous NTN4 act as a survival factors in cells with 
different levels of endogenous NTN4.
NTN4 as a survival factor through NEO1 
signaling
Apoptosis increases when NEO1 is overexpressed, 
revealing its death dependence function [8]. This effect 
was reverted using exogenous Netrin-4. In addition, when 
NEO1 is silenced in a shNTN4 background, the apoptosis 
induction by the NTN4 knock-down is reverted, indicating 
that NTN4 is a survival factor modulating dependence 
receptor NEO1’s pro-apoptotic downstream signaling. 
In addition, Netrin-4 did not reduced the apoptosis of 
cells overexpressing TrkC indicating that NTN4 acts as 
a survival factor specifically through NEO1. Thus, the 
NEO1/NTN4 signaling complex modulates a balance 
between survival and apoptosis in these cells. NTN1, 
another NEO1 ligand, is overexpressed in aggressive NB 
and is also considered a survival factor [18]. Although 
LAN-1 express NTN1, NTN4 acts probably as the main 
NEO-1-related survival factor in these cells, since cell 
death is triggered when NTN4 is silenced. Likewise, it 
has been shown in NB that NTN1 could act as a survival 
factor through UNC5H downstream signaling [18].
Usually, dependence receptors act as tumor 
suppressors [11]. However, NEO1 knock-down does 
not reduce cell death and its expression is maintained in 
several cancer cells, such as NB [30] and medulloblastoma 
[6]. We propose that autocrine NTN4 expression through 
NEO1 binding allows sustained NEO1 function in these 
tumors, maintaining cells in a pro-survival state.
NEO1 acts via NTN4 in NB cell migration
In this work, we show that NEO1 is involved in NB 
cell migration, acting via its ligand NTN4. In other cell 
types, such as gastric cancer, NEO1 modulates the effect 
of endogenous NTN4 on motility [21]. The overexpression 
of NEO1 in gastric cancer increases cell motility, acquiring 
a migratory phenotype [36], and its knock-down reduces 
cell migration in the same cell types [21]. Researchers 
have stated these observations in other contexts, and, 
so far, no data have demonstrated the dose-dependent 
chemotactic behavior of NEO1 in NB cells.
Evaluating the effects of cell-matrix and cell-
cell interactions via wound healing assays revealed that 
NEO1 SK-N-SH knock-down cells significantly reduce 
cell migration compared with shSCR (control) and 
shNTN4 knock-down cells. Endogenous NTN4, under 
these conditions, did not influence cell migration. But 
it is worth mentioning that our experimental conditions 
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included low serum supplementation, which contains 
NTN4 as well as other Netrin ligands (data not shown). 
Thus, we also performed transwell assays in the absence 
of serum to evaluate the role and contribution of NTN4 
to cell migration and the competence of NEO1 to sense 
NTN4 chemotactic stimulus. Knocking down NTN4 
did not result in an increase in cell migration compared 
to the condition without a chemotactic stimulus, hence 
suggesting that endogenous NTN4 maintains cells in a 
pro-migratory state. Contrary to SK-N-SH, LAN-1 cells do 
express NTN1 and shNTN4 cells migrate sensing NTN4 
chemoattraction; most probably NTN1 compensates 
the NTN4 function in these cells. Furthermore, there is 
evidence that demonstrates the binding of NTN4 and 
NTN1 to other non-canonical Netrin receptors, such as 
Integrins (α6β1, [26]), which might explain a NEO1-
independent Netrin compensation. We observed that 
shNEO1 cells did not migrate more than in a condition 
without stimulus. These cells cannot sense the NTN4 
stimulus, highlighting the importance of NEO1 in guiding 
cells to migrate. Overexpressing NEO1 resulted in greater 
cell migration compared to control cells, confirming that 
NEO1 has an essential role in promoting cell migration.
The dependency of NB cells to migrate through 
NEO1 was revealed when we overexpressed NEOICD 
in SK-N-SH. NEOICD cells cannot bind Netrins and, 
consequently, the cells did not migrate efficiently. This 
result also confirms the possibility that endogenous 
NTN4 is binding to the NEO1 receptor on the cell 
surface, activating its intracellular pro-migratory cascade, 
possibly through focal adhesion kinase (FAK) signaling. 
During neuronal migration and axonal guidance, NEO1 
binds to FAK [37]. FAK is fundamental for focal 
adhesion dynamics and cell migration [38]. Therefore, 
NEO1 promotes cell migration, guiding the cells via the 
NTN4 chemotactic stimulus. This is relevant in NB cells, 
because the molecular mechanisms that mediate neural 
crest delamination are also likely to be involved in NB 
migration [39]. The data suggest that NEO1, expressed in 
DRG, is involved in the symphatoadrenal-lineage neural-
crest cells migration during embryonic development. DCC 
is involved in the migration of neural crest cells in the 
formation of the bowel and pancreas [40], acting through 
NTN1 as a guidance molecule; as a homolog, NEO1 
may also participate in this process. The role of NEO1 is 
probably conserved, although intracellular pathways are 
not shared between NEO1 and DCC. In axonal guidance 
for example, DCC selectively interacts with Src family 
kinases Fyn and Lck intracellularly [41], while NEO1 
interacts additionally with SHIP1 phosphatase. The 
different molecules involved in each signaling pathway 
may explain the differences between NEO1 and DCC 
signaling in tumoral suppression. The evidence provided 
by others and the results presented here, collectively, 
indicate that NEO1 acts by primarily promoting tumoral 
migration and survival through its ligands produced by the 
tumoral cells [18], stroma [42], or lamina basal [7], while 
DCC acts mostly as a pro-apoptotic molecule [43], which 
expression is reduced in several tumors as NB [31] among 
others.
Convergence of functions of NEO1/NTN4 in 
tumor progression
NEO1 and NTN4 knock-down cells generate 
primary tumors in CAMs, with similar weight and size 
compared with control tumors (shSCR). The CAM itself 
produces survival factors [44] and its vessels irrigate 
the tumors, reducing pro-apoptotic signals, which could 
explain the similar behavior of shSCR, shNEO1 and 
shNTN4 cells. As CAM cells migrate, the NEO1/NTN4 
signaling complex becomes increasingly more important, 
deduced by the formation of secondary tumors near the 
primary tumors of SK-N-SH shSCR cells. shNEO1 and 
shNTN4 cells lacked secondary tumors, reinforcing 
the idea that the NEO1/NTN4 complex is biologically 
pivotal for cell migration process in vivo. Metastasis 
is a complex process that involves cell migration and 
invasion. When we evaluated the role of NEO1 in this 
latter process, we observed that NEO1 knock-down cells 
have a reduced capacity to form secondary tumors and 
to metastasize to lungs, revealing an impaired migration. 
Thus, NTN4 is also required for metastasis. This result 
suggests that NTN4 maintains the cells in a pro-migratory 
state in coordination with NEO1, activating intracellular 
signals. Physiologically, we hypothesize that as metastasis 
commences, NEO1 expressing cells sense the NTN4 
gradients produced by the Netrin-producing cells, mainly 
located in the lamina basal of endothelia [7]. Therefore, 
NEO1 may have an active role in metastasis by sensing 
ligand gradients, promoting NTN4-guided intravasation, 
and colonizing new cancerous niches.
This work suggests that NEO1 acts as a tumoral 
progression-promoting protein, with an active role in 
metastasis, resembling its function in developmental 
cell migration. NEO1 itself induces apoptosis in certain 
contexts but within the context of cancer, in addition to 
autocrine ligand production, the stroma and/or basal 
lamina of vessels produce Netrins, thereby increasing the 
capacity of cells to migrate guided by NEO1. In cancer 
onset NEO1 might govern cell cycle kinetics and survival 
[6], while in aggressive tumor cells, NEO1 may function 
promoting cell migration. Different NTN4 availability 
might account for a differential behavior of NEO1 in 
vivo [36]. Further work is required to delineate the 
associated cellular mechanism required for cell survival 
and migration guided by NEO1 through ligand gradients, 
such as NTN4.
MYCN amplification and NEO1 and NTN4 
expression
As MYCN amplification is associated with 
NB aggressiveness and poor prognosis (MYCN 
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protein expression as a predictor of neuroblastoma 
prognosis) [45], we evaluated the relation in between 
MYCN amplification and NEO1/NTN4 expression. 
According with Versteeg data set [23], there is not 
difference in NEO1 expression in tumor samples with 
or without MYCN amplification (Supplementary Figure 
4A). By contrast, MYCN amplified tumor samples have 
more NTN4 expression (Supplementary Figure 4B), which 
is in line with the expression data observed in NB cell 
lines analyzed in this work. It is important to emphasize 
the complexity of the NEO1 signaling pathway, and how 
NTN4 acts through NEO1 regardless of MYCN status. 
Therefore, NEO1 could be one of the main regulators of 
survival and migration in NB.
On the other hand, there is controversy about NTN1 
expression in MYCN amplified tumors. In the same data 
set, its shown that NTN1 is less expressed in MYCN 
amplified tumors (Supplementary Figure 4C), which 
does not correspond with cell lines analyzed in this work 
and with other literature, which shows that there is not 
an association between NTN1 up-regulation and MYCN 
amplification [18]. NTN1 Kapplan Meier survival plots 
(Supplementary Figure 1B), show that NTN1 expression 
is a good survival prognosis factor, which is contrary 
with the MYCN amplification in NB aggressiveness. 
Importantly, previous report [18], have shown that NTN1 
survival function is via UNC5H, and not through NEO1. 
This controversy shows that NTN1 regulation is complex 
and needs further analysis.
In conclusion, NTN4 and its receptor NEO1 
promote cell migration, survival, and metastasis in NB 
cells. The NTN4/NEO1 signaling complex balances 
apoptosis and survival. If NTN4 is not expressed, 
NEO1 induces cellular apoptosis. However, if NTN4 is 
expressed, NEO1 signaling promotes cellular survival and 
migration. All these results underlie that there is a delicate 
balance between apoptosis and cell migration.
NEO1 signaling is becoming an attractive target for 
use in cancer therapies [6, 46]. Based on our results, we 
propose that NEO1 and/or NTN4 are promising targets 
for use anti-cancer therapies, in particular to inhibit the 
tumoral metastasis. Considering the ultimate efforts in 
the clinical and genomic medicine field, directed towards 
the generation of new therapeutic strategies, we could 
envision the development of inhibitors of the extracellular 
recognition of NTN4 by NEO1, allowing thus the 
modulation of NEO1 activity in an extracellular fashion.
MATERIALS AND METHODS
Cell culture
Neuroblastoma cell lines SH-SY5Y, SK-N-SH, 
LAN-1 and, NB1691 were cultured in high glucose 
Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) 
with 5% (SK-N-SH) or 10% (LAN-1, NB1691) fetal 
bovine serum (FBS, Gibco) and supplemented with 
antibiotics (Penicillin-Streptomycin, 10,000 U/mL). The 
U87 (glioblastoma), HEK293 (human embryonic kidney) 
and DAOY (medulloblastoma) cell lines were cultured in 
DMEM with 10% FBS supplemented with antibiotics.
Western blots
Protein extraction was realized using lysis buffer 
(SDS 2% w/v, Tris-HCL 80 mM pH 7.5, Glycine 10% 
w/v) with protease inhibitors (Thermo). After three 
minutes of sonication at ice-cold temperature, samples 
were centrifuged (10000 × g) for 5 minutes at 4°C. 
The antibodies used were anti-Neo1 (#sc-6536, Santa 
Cruz Biotechnology), anti-DCC (#sc-6535, Santa Cruz 
Biotechnology), anti-Netrin-1 (AF6419, R&D systems), 
anti-NTN4 (HYR01, R&D systems), anti-RGMa 
(AF2459, R&D systems), anti-actin (A5316, Sigma), and 
anti-tubulin (T9026, Sigma). Primary antibodies were 
incubated overnight at 4°C in 5% non-fat milk diluted 
in TBS-Tween 0,01% and secondary antibodies were 
incubated at room temperature for two hours in the same 
buffer. Western blots were quantified using integrated 
density analysis with ImageJ software (National Institutes 
of Health, USA).
Protein co-immunoprecipitation
SK-N-SH cells were incubated with human 
recombinant Netrin-4 (200 ng/ml) for 1h. Later, cell 
extracts were prepared in a buffer containing 20 mM Tris, 
pH 7.4, 150 mM NaCl, 1% NP-40, and protease inhibitors 
by 5 min incubation on ice. Samples were centrifuged 
at 13,000 × g by 1 min at 4°C, and supernatants (1000 
μg total protein) were immunoprecipitated with 
protein A/G bead-immobilized antibodies for 1h. 
NEO1 was immunoprecipitated with 5 μg of a rabbit 
polyclonal antibody (H-175 Santa Cruz) and NTN4 was 
immunoprecipitated with 5 μg of NTN4 goat polyclonal 
antibody. Immunoprecipitated samples were solubilized in 
loading buffer with ß-mercaptoethanol, and analyzed by 
Western blot as indicated in the Figure 1.
Quantitative PCR
We used real-time quantitative PCR (qPCR) to 
identify and quantify the expression of NTN4 in NB cells. 
The cell cultures were maintained in 10% FBS until 90% 
confluence, where they were used for RNA extraction using 
RNAsolv (OMEGA, R6830-02). Purified RNA was used 
for cDNA synthesis using Revertaid Reverse Transcriptase 
(Thermo scientific) according to the manufacturer’s 
instructions. The primers used for qPCR analysis were: 
NTN4 (Fw: 5’ TCAGCACAACACAGAAGGACA3’; 
Rv: 5’ GGATGGCAGGAACACGGTTTG 3’), and 
40 PCR cycles were used in the experiments, at an 
Oncotarget9779www.impactjournals.com/oncotarget
annealing temperature of 60°C. Gene expression values 
were graphed as a fold change with respect to GAPDH 
(Fw: 5’ CAAGAAGGTGGTGAAGCAGGC3’; Rv: 
5’CCACCACCCTGTTGCTGTAG3’). PCR amplification 
was verified via gel electrophoresis.
Lentiviral transduction and stable shRNAs cell 
line generation
To knock-down NEO1 (shNEO1) and NTN4 
(shNTN4), SK-N-SH and LAN-1 cells were transduced 
through lentiviral particles that contain shRNAs (pGIPZ 
backbone) vectors for each gene of interest [6]. A scramble 
sequence (shSCR) was used as a control. Lentiviral 
particles were prepared as indicated in [47]. Briefly, HEK 
293T cells were triple transfected with pCMV-VSV-G, 
p8.91, and pGIPZ-shRNA (Openbiosystems). Viral 
supernatants were harvested 48 hours after transfection, 
filtered through 0.45-mm cellulose acetate filters, and 
them were used to transduce SK-N-H and LAN-1 cultured 
with this medium mixed with DMEM 5% FBS. After 48 
hours, the transduction percentage was measured using 
tGFP encoding in pGIPZ and cells were incubated with the 
selection marker puromycin (3 μg/ml for SK-N-SH and 
1μg/ml LAN-1, Sigma) for an additional 48 hours. Cells 
were maintained in DMEM with FBS supplemented with 
puromycin. The knock-down efficiency was measured via 
Western blot analysis.
NEO1GFP and NEO1ICDGFP overexpression
The plasmids used to overexpress Neo1GFP and 
NeoICD (intracellular domain of NEO1) fragments were 
a kind donation from Dr. Patrick Mehlen (Université 
de Lyon, Centre Léon Bérard, Lyon, France), and were 
prepared as described in [48]. The backbone used for the 
plasmids was pEGP-C1, which has an eGFP sequence 
in frame with NEO1 or NEOICD sequence. The TrkC-
overexpression plasmid was also a donation from Dr. 
Patrick Mehlen and the backbone used for the plasmid was 
pCDNA3, described in [49]. The transfection was made in 
SK-N-SH cells using Turbofect (Thermofisher) according 
to the manufacturer´s instructions.
Wound healing assay
The wound healing assay was carried out using SK-
N-SH shNEO1, shNTN4, and shSCR cells as described in 
[50], with some modifications. Briefly, cells were cultured 
for 24h to reach confluence. Then, a scratch was made 
with a micropipette tip in the center of the plate in order 
to generate a space between cells. The cells were washed 
with phosphate buffered saline (PBS) and incubated in 
DMEM 2.5% FBS. The plates were photographed using 
a microscope (Motic) coupled to digital camera (Leica) 
at 100x of total amplification, setting this at time 0. Cells 
were incubated for 9h and then photographed using the 
same conditions. This experiment was carried out in 
quadruplicate. The analysis was made using Image J 
software and the data are shown as a percentage of wound 
healing (closure) of each cell type.
Transwell migration assays
Tranwell assays were completed using a chamber 
within an 8μm-pore polycarbonate membrane (Corning). 
As a haptotactic stimulus, 2μg/μl fibronectin was used 
(Sigma Aldrich), placed on the bottom of the membrane 
12h before performing the assay. As a chemotactic 
stimulus, different concentrations of human recombinant 
Netrin-4 (R&D Systems) diluted in DMEM (without FBS) 
were used; the concentrations are indicated in Figure 4. 
Briefly, for SK-N-SH, 50,000 shNEO1, shNTN4, and 
shSCR cells were placed in the upper chamber; the bottom 
chamber contained NTN4 diluted in DMEM. The cells 
were incubated for 4h, fixed, and stained using Crystal 
violet 100% diluted in methanol in a solution 1:5 of NaCl 
0,15M. For LAN-1 100,000 shNEO1, shNTN4, and 
shSCR cells were placed in the upper chamber; the bottom 
chamber contained 100 ng/ml Netrin-4 diluted in DMEM. 
The cells were incubated for 6h, fixed, and stained same 
as SK-N-SH cells.
To determine if NEO1-overexpressed cells 
migrate more in transwell assay than control cells in the 
presence of a Netrin-4 stimulus (100ng/mL), SK-N-SH 
cells overexpressing EV (empty vector), NEO1GFP, or 
NEO1ICDGFP were used. The results were normalized 
according to condition without Netrin-4 for each 
experiment.
Immunofluorescence
Double-immunofluorescence were completed with 
anti-cleaved Caspase-3 (9661, Cell Signaling) and anti-
Tubulin (T9026, Sigma) in SK-N-SH shNTN4 and shSCR 
cells. The cells were cultured in 24-well plates for 24h. 
Subsequently, they were deprived of FBS, and exogenous 
Netrin-4 was added for 24h. Human recombinant RGMa 
(100ng/mL) was used as a control. Cell nuclei were also 
stained with a DAPI (Sigma Aldrich).
To evaluate proliferation, SK-N-SH shNTN4, 
and shSCR cells were incubated with BrdU (Sigma) 
for 1h in 24-well plates in DMEM 2,5% FBS. Then, 
the cells were fixed with 4% paraformaldehyde (PFA) 
and immunostained with anti-BrdU (DAKO) and 
phosphohistone3 (Millpore) antibodies following the 
protocol as explained previously. Fluorescence microscopy 
was performed using an Olympus BX- 51 microscope. A 




LAN-1 cells shSCR and shNTN4 were culture in 
96-well plates. After 24 h, cells were serum deprived 
by 24h. To evaluate dead cells, cells were stained with 
Propidium iodide (PI) and Hoechst at final concentration 
of 1 μg/ml and 5 μg/ml, respectively. Cells were analyzed 
and counted using Cytell Cell Imaging System (GE 
Healthcare), using Cell Viability BioApp (GEHealthcare). 
Ten fields were analyzed per well and average per well 
were grafted. The assay was made by six replicates for 
each condition and two independent experiments were 
realized for the assay.
TUNEL assay
TUNEL assays were conducted utilizing the 
ApopTag® Fluorescein Direct in Situ Apoptosis Detection 
Kit (Merck Millipore), following the manufacturer's 
instructions, to measure apoptosis in shNTN4, shSCR, 
and NEO1-overexpressing SK-N-SH cells. Cells were 
incubated in Netrin-4 (200ng/mL) diluted in DMEM 
for 24h. We used DMEM without FBS as an incubation 
control. The assays were analyzed by fluorescence 
microscopy using an Olympus BX- 51 microscope. 
TUNEL positive cells and DAPI positive cells were 
counted and the ratio between both quantifications was 
graphed as a percentage.
siRNA transfection
To evaluate the contribution of NEO1 in the 
apoptosis induced by NTN4 knock-down, we transfected 
siRNAs against NEO1 in shNTN4 SK-N-SH cells using 
Turbofect (Thermofisher) according to manufacture’s 
instructions. The sequences correspond to siNEO1(1) 
(SASI_Hs02_00333957) and siNEO1(2) (SASI_
Hs01_00151269) and, siControl (SIC002) provided by 
Sigma Aldrich. siRNA efficiency was evaluated through 
Western blot against NEO1. Briefly, 1μg of siRNA was 
transfected into shNTN4 cells and 48 h later, cells were 
serum deprived for 48h and fixed with PFA 4%. Apoptosis 
was evaluated via TUNEL and immunofluorescence 
of Cleaved-Caspase-3. The assays were analyzed by 
fluorescence microscopy using an Olympus BX- 51 
microscope. Positive cells and DAPI positive cells 
were counted and the ratio between both quantifications 
was graphed as a percentage. The assays were made by 
30 replicates for each condition and two independent 
experiments were realized for each assay.
Metastasis analysis via CAM assays
Fertilized chicken eggs were incubated at 37.5°C 
with constant humidity. On the second day of incubation 
(E2), 2 mL of albumin was removed from the egg. On 
day four (E4), a rounded window was made in the shell 
in order to have access to the chick chorioallantoic 
membrane (CAM), and sealed with adhesive tape. On 
day ten of incubation (E10), ten million SK-N-SH 
shNEO1, shNTN4, or shSCR cells were drop-plated on 
the developing CAM. On day 17 of incubation (E17), 
the primary tumor of the CAM was weighed and the 
embryo was dissected. Embryonic lungs were incubated 
with RNASolv (OmegaBiotek) and kept at -20°C. We 
extracted genomic DNA following the manufacturer’s 
instructions. Genomic DNA expression levels were 
analyzed via qPCR analysis using human Alu sequences 
(FW: 5’ACG CCT GTA ATC CCA GCA CTT3’; RV: 
5’TCG CCC AGG CTG GAG TGC A3’) and genomic 
chicken GAPDH (FW: 5’GAG GAA AGG TCG CCT 
GG3’; RV: 5’GGT GAG GAC AAG CAG TGA3’) 
primers. The analysis was made using fold change with 
respect to chGAPDH and normalized according to lung 
of control cells (shSCR). Five eggs were used for each 
condition.
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